Medicare Part D will cover popular weight loss drugs like Wegovy and Ozempic starting in 2026, with copays capped at $50 per ...

With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...

The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research. Current ...

Most Democratic-led states will continue to recommend the hepatitis B vaccine at birth, despite a CDC advisory panel’s vote ...

U.S. pharmaceutical companies have recently begun selling some medications through "direct-to-consumer" channels, The Wall Street Journal (WSJ) reported on the 8th. Instead of relying on decades-old ...

The 2026 update to the ADA’s Standards of Care in Diabetes introduces new guidance on a wide range of topics, including the ...

A new WHO guideline on GLP-1s and recent efforts to reduce the drugs’ costs now and going forward are unlikely to change US ...

They're leading to reduced grocery spending, healthier food choices, wardrobe changes, and altered dining habits. The drugs ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Here's the good news for anyone wondering if Medicare provides coverage for treatment of substance use disorders: It does. But the bad news is that there's a lot of fine print to be aware ...

Some patients dropped out of the trial early because they had lost so much weight.

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...